Enavate Sciences GP, LLC
13F Reported Value
ⓘ$351.5M
Holdings
7
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Enavate Sciences GP, LLC disclosed 7 positions worth $351.5M in its Form 13F-HR for Q1 2026, led by $SION (Sionna Therapeutics, Inc.) at 28.3% of the equity portfolio, followed by $IMNM and $ZBIO. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Enavate Sciences GP, LLC’s Form 13F-HR filing with the SEC under CIK 1953107.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$99.3M2,478,030 sh - 5.8#2,844
Quality
$79.0M3,613,799 sh - 14.4#2,761
Quality
$76.6M3,919,159 sh - —
Quality
$41.2M7,788,150 sh - $23.5M2,626,946 sh
- 22.6
Quality
$22.1M2,459,703 sh - 23.3
Quality
$9.7M2,190,920 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Sionna Therapeutics, Inc.$SION | — | $99.3M | 2,478,030 |
 Immunome Inc.$IMNM | 5.8#2,844 | $79.0M | 3,613,799 |
 Zenas BioPharma, Inc.$ZBIO | 14.4#2,761 | $76.6M | 3,919,159 |
 Compass Therapeutics, Inc.$CMPX | — | $41.2M | 7,788,150 |
 BridgeBio Oncology Therapeutics, Inc.$BBOT | — | $23.5M | 2,626,946 |
 Upstream Bio, Inc.$UPB | 22.6 | $22.1M | 2,459,703 |
 Camp4 Therapeutics Corp$CAMP | 23.3 | $9.7M | 2,190,920 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Enavate Sciences GP, LLC's 7 positions.
Showing top 7 of 7 holdings.
Sector Allocation
Healthcare
$351.5M
Full Holdings — Enavate Sciences GP, LLC (Q1 2026)
All 7 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SION | Sionna Therapeutics, Inc. | $99.3M | 28.3% | +0% | — |
| 2 | $IMNM | Immunome Inc. | $79.0M | 22.5% | -24% | 5.8 |
| 3 | $ZBIO | Zenas BioPharma, Inc. | $76.6M | 21.8% | +0% | 14.4 |
| 4 | $CMPX | Compass Therapeutics, Inc. | $41.2M | 11.7% | +0% | — |
| 5 | $BBOT | BridgeBio Oncology Therapeutics, Inc. | $23.5M | 6.7% | +0% | — |
| 6 | $UPB | Upstream Bio, Inc. | $22.1M | 6.3% | +0% | 22.6 |
| 7 | $CAMP | Camp4 Therapeutics Corp | $9.7M | 2.8% | -28% | 23.3 |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Enavate Sciences GP, LLC including:
Track Enavate Sciences GP, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Enavate Sciences GP, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Enavate Sciences GP, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Enavate Sciences GP, LLC (SEC CIK: 1953107), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Enavate Sciences GP, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.